Three COVID-19 Drugs Clear UK Funding Hurdle But Olumiant No Longer In The Running
Executive Summary
NICE says it is the first health technology assessment body to look at the non-pandemic use of COVID-19 treatments. It is also planning to launch a consultation on a new process for updating its recommendations on such products with a view to making them available more quickly if new variants emerge.
You may also be interested in...
NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.
UK’s NICE Says No To AstraZeneca’s Evusheld Amid ‘Rapidly Changing’ COVID-19 landscape
NICE says that limitations in the evidence for Evusheld make it difficult to produce a reliable cost-effectiveness estimate.
Lilly Pulls EU Approval Application For Olumiant In COVID-19
The European Medicines Agency says it does not have enough data to justify the approval of Olumiant for hospitalized COVID-19 patients. The marketing authorization application for another product, Reata’s Imbarkyd for chronic kidney disease, has also been withdrawn.